CD135 (FLT3 receptor) expression as an indicator of prognosis in patients with de novo acute myeloid leukemia
A blood marker predicts which acute leukemia patients respond poorly to standard treatment and may benefit from targeted therapy combinations.
In 214 de novo AML patients (plus external validation cohort N=78), high CD135 (FLT3 receptor) surface expression was independently associated with lower induction response and worse overall/progression-free survival. A nomogram incorporating CD135 achieved AUC 0.817 in development and 0.722 in multicenter validation, and high-CD135 FLT3-ITD patients demonstrated significant OS benefit from TKI combination therapy.
What the study was
- Study design
- Retrospective multicenter cohort with external validation
- Population
- De novo AML patients at Soochow University and affiliated centers; China
- Sample size
- 292
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Annals of Hematology
Why it surfaced
Multicenter validation of CD135 as prognostic biomarker in AML with actionable therapeutic stratification for FLT3-ITD patients. Retrospective design limits causal inference but multicenter validation is meaningful for a hematologic malignancy topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.